41 results on '"Pieber, Thomas R."'
Search Results
2. Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial.
- Author
-
Sourij, Caren, Oulhaj, Abderrahim, Aziz, Faisal, Tripolt, Norbert J., Aberer, Felix, Pferschy, Peter N., Postula, Marek, Drexel, H., Benedikt, Martin, Kolesnik, Ewald, Pieber, Thomas R., Bugger, Heiko, von Lewinski, Dirk, and Sourij, Harald
- Subjects
SODIUM-glucose cotransporters ,MYOCARDIAL infarction ,SODIUM-glucose cotransporter 2 inhibitors - Abstract
The article discusses a study that examined the effects of empagliflozin, a medication used to treat diabetes, on heart function in patients who had a heart attack. The study found that the medication had similar effects on heart function regardless of the patients' blood sugar levels. The results are consistent with previous research showing the benefits of empagliflozin in heart failure patients. However, more research is needed to fully understand the long-term effects of the medication in heart attack patients. The study was funded by a grant and the authors have no conflicts of interest. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
3. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
- Author
-
Amod, Aslam, Buse, John B., McGuire, Darren K., Pieber, Thomas R., Pop-Busui, Rodica, Pratley, Richard E., Zinman, Bernard, Hansen, Marco Bo, Jia, Ting, Mark, Thomas, and Poulter, Neil R.
- Published
- 2020
- Full Text
- View/download PDF
4. Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes.
- Author
-
Pieber, Thomas R., Asong, Marisse, Fluhr, Gabriele, Höller, Vera, Kristensen, Niels R., Larsen, Jonas H., Ribel‐Madsen, Rasmus, Svehlikova, Eva, Vinther, Siri, Voortman, Margarete, and Haahr, Hanne
- Subjects
- *
TYPE 2 diabetes , *INSULIN derivatives , *PHARMACOKINETICS , *INSULIN , *GLUCOSE clamp technique , *BODY mass index , *BLOOD sugar - Abstract
Aims: To characterize the pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in type 2 diabetes (T2D). Materials and Methods: In an open‐label trial, 46 individuals with T2D (18‐75 years; body mass index 18.0‐38.0 kg/m2; glycated haemoglobin ≤75 mmol/mol [≤9%]; basal insulin‐treated) received subcutaneous once‐weekly icodec for ≥8 weeks at individualized doses, aiming at a pre‐breakfast plasma glucose concentration of 4.4 to 7.0 mmol/L (80‐126 mg/dL) on the last three mornings of each weekly dosing interval. Frequent blood sampling to assess total serum icodec concentration (ie, albumin‐bound and unbound) occurred from first icodec dose until 35 days after last dose. Icodec trough concentrations following initiation of once‐weekly dosing were predicted by pharmacokinetic modelling. During the final 3 weeks of icodec treatment, while at steady state, the icodec glucose‐lowering effect was assessed in three glucose clamps (target 7.5 mmol/L [135 mg/dL]): 0 to 36, 40 to 64 and 144 to 168 h post‐dose, thus covering the initial, middle and last part of the 1‐week dosing interval. Glucose‐lowering effect during a complete dosing interval was predicted by pharmacokinetic‐pharmacodynamic modelling. Results: Model‐predicted icodec steady state was attained after 3 to 4 weeks. At steady state, model‐predicted daily proportions of glucose‐lowering effect on days 1 to 7 of the 1‐week dosing interval were 14.1%, 16.1%, 15.8%, 15.0%, 14.0%, 13.0% and 12.0%, respectively. Icodec duration of action was at least 1 week in all participants. Once‐weekly icodec was overall safe and well tolerated in the current trial. Conclusions: The pharmacokinetic and pharmacodynamic characteristics of icodec in individuals with T2D support its potential as a once‐weekly basal insulin. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Combined metformin-associated lactic acidosis and euglycemic ketoacidosis
- Author
-
Schwetz, Verena, Eisner, Florian, Schilcher, Gernot, Eller, Kathrin, Plank, Johannes, Lind, Alice, Pieber, Thomas R., Mader, Julia K., and Eller, Philipp
- Published
- 2017
- Full Text
- View/download PDF
6. Glucose Metabolism and Metabolomic Changes in Response to Prolonged Fasting in Individuals with Obesity, Type 2 Diabetes and Non-Obese People—A Cohort Trial.
- Author
-
Tripolt, Norbert J., Hofer, Sebastian J., Pferschy, Peter N., Aziz, Faisal, Durand, Sylvère, Aprahamian, Fanny, Nirmalathasan, Nitharsshini, Waltenstorfer, Mara, Eisenberg, Tobias, Obermayer, Anna M. A., Riedl, Regina, Kojzar, Harald, Moser, Othmar, Sourij, Caren, Bugger, Heiko, Oulhaj, Abderrahim, Pieber, Thomas R., Zanker, Matthias, Kroemer, Guido, and Madeo, Frank
- Abstract
Metabolic regulation of glucose can be altered by fasting periods. We examined glucose metabolism and metabolomics profiles after 12 h and 36 h fasting in non-obese and obese participants and people with type 2 diabetes using oral glucose tolerance (OGTT) and intravenous glucose tolerance testing (IVGTT). Insulin sensitivity was estimated by established indices and mass spectrometric metabolomics was performed on fasting serum samples. Participants had a mean age of 43 ± 16 years (62% women). Fasting levels of glucose, insulin and C-peptide were significantly lower in all cohorts after 36 h compared to 12 h fasting (p < 0.05). In non-obese participants, glucose levels were significantly higher after 36 h compared to 12 h fasting at 120 min of OGTT (109 ± 31 mg/dL vs. 79 ± 18 mg/dL; p = 0.001) but insulin levels were lower after 36 h of fasting at 30 min of OGTT (41.2 ± 34.1 mU/L after 36 h vs. 56.1 ± 29.7 mU/L; p < 0.05). In contrast, no significant differences were observed in obese participants or people with diabetes. Insulin sensitivity improved in all cohorts after 36 h fasting. In line, metabolomics revealed subtle baseline differences and an attenuated metabolic response to fasting in obese participants and people with diabetes. Our data demonstrate an improved insulin sensitivity after 36 h of fasting with higher glucose variations and reduced early insulin response in non-obese people only. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective.
- Author
-
Aberer, Felix, Pieber, Thomas R., Eckstein, Max L., Sourij, Harald, and Moser, Othmar
- Subjects
- *
TYPE 1 diabetes , *RANDOMIZED controlled trials , *CLINICAL trials , *INSULIN , *CARDIOVASCULAR diseases risk factors , *TYPE 2 diabetes - Abstract
Background: In Type 1 diabetes (T1D), according to the most recent guidelines, the everyday glucose-lowering treatment is still restricted to the use of subcutaneous insulin, while multiple therapeutic options exist for Type 2 diabetes (T2D). Methods: For this narrative review we unsystematically screened PubMed and Embase to identify clinical trials which investigated glucose-lowering agents as an adjunct to insulin treatment in people with T1D. Published studies up to March 2022 were included. We discuss the safety and efficacy in modifying cardiovascular risk factors for each drug, the current status of research, and provide a clinical perspective. Results: For several adjunct agents, in T1D, the scientific evidence demonstrates improvements in HbA1c, reductions in the risk of hypoglycemia, and achievements of lower insulin requirements, as well as positive effects on cardiovascular risk factors, such as blood lipids, blood pressure, and weight. As the prevalence of obesity, the major driver for double diabetes, is rising, weight and cardiovascular risk factor management is becoming increasingly important in people with T1D. Conclusions: Adjunct glucose-lowering agents, intended to be used in T2D, bear the potential to beneficially impact on cardiovascular risk factors when investigated in the T1D population and are suggested to be more extensively considered as potentially disease-modifying drugs in the future and should be investigated for hard cardiovascular endpoints. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Assessment of Two Different Glucagon Assays in Healthy Individuals and Type 1 and Type 2 Diabetes Patients.
- Author
-
Brunner, Martina, Moser, Othmar, Raml, Reingard, Haberlander, Maximilian, Boulgaropoulos, Beate, Obermayer-Pietsch, Barbara, Svehlikova, Eva, Pieber, Thomas R., and Sourij, Harald
- Subjects
TYPE 1 diabetes ,TYPE 2 diabetes ,GLUCAGON ,PEOPLE with diabetes ,ENZYME-linked immunosorbent assay - Abstract
Methods for glucagon analysis suffered in the past from lack of specificity and a narrow sensitivity range, which has led to inaccurate results and to the suggestion that type 1 diabetes (T1D) and type 2 diabetes (T2D) patients have elevated fasting glucagon levels. However, the availability of more specific and more sensitive methods to detect intact glucagon has shown that actual glucagon levels are lower than previously assumed. This study aimed to characterize fasting plasma glucagon levels in healthy individuals and T1D and T2D patients with two different glucagon assays. The study included 20 healthy individuals, 20 T1D and 20 T2D patients. Blood was collected under fasting conditions. A double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) and a conventional radioimmunoassay (RIA) were used. A significant difference in fasting glucagon levels between healthy individuals and T2D was observed by ELISA, but not by RIA. ELISA also yielded lower glucagon levels in healthy individuals than in T1D and T2D patients which RIA did not. RIA produced significantly (p = 0.0001) higher overall median glucagon values than ELISA in a pooled analysis. These results underline the notion that the choice of selective laboratory methods is highly relevant for mechanistic endocrine research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.
- Author
-
Pieber, Thomas R., Bajaj, Harpreet S., Heller, Simon R., Jia, Ting, Khunti, Kamlesh, Klonoff, David C., Ladelund, Steen, Leiter, Lawrence A., Wagner, Lily, and Philis‐Tsimikas, Athena
- Subjects
- *
TYPE 2 diabetes , *INSULIN aspart , *KIDNEY physiology , *INSULIN , *TYPE 1 diabetes , *GLYCEMIC control - Abstract
Keywords: insulin analogues; insulin therapy; type 2 diabetes EN insulin analogues insulin therapy type 2 diabetes 332 336 5 01/11/22 20220201 NES 220201 PEER REVIEW The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14564. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. HbA1c levels and rates of hypoglycemia with insulin degludec U200 and insulin glargine U300 stratified by estimated renal function in people with type 2 diabetes: a post hoc analysis from the CONCLUDE trial. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
10. Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.
- Author
-
Tarride, Jean-Eric, Husain, Mansoor, Andersen, Andreas, Gundgaard, Jens, Luckevich, Maria, Mark, Thomas, Wagner, Lily, and Pieber, Thomas R.
- Subjects
CARDIOVASCULAR diseases risk factors ,TYPE 2 diabetes ,MEDICAL care costs ,RANDOMIZED controlled trials ,CONFIDENCE intervals - Abstract
Objectives: The present cost-consequence analysis compared estimated hospitalization costs in a Canadian setting with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk. Methods: Medical terms were mapped across the different vocabularies, in order to assign unit costs from eligible hospital abstracts in Canadian Institute for Health Information data (International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Canada) to serious adverse events (SAEs; Medical Dictionary for Regulatory Activities) from the randomized DEVOTE trial comparing the two insulins degludec and glargine. Mean annual costs of SAE-related hospitalizations were estimated by treatment, the cost difference (degludec-glargine U100) was bootstrapped to compute confidence intervals (CIs) and p-values, and the cost ratio (degludec/glargine U100) was estimated using a Tweedie distribution. Results: The mean annual cost per patient for SAE-related hospitalizations was 4,074 CAD with degludec and 4,569 CAD with glargine U100 (cost difference: -495, 95% confidence interval [CI]: -966; -24, p=.039), for a cost ratio of 0.89 (95% CI: 0.81; 0.98, p=.016). Overall, cost ratios from sensitivity analyses varying individual methodological assumptions were consistent with the main analysis. Of the system organ classes from DEVOTE SAEs, cardiac disorders were the largest contributor to the costs savings with degludec versus glargine U100. Conclusions: In patients with T2D at high CV risk, our findings suggest that there are likely to be lower hospitalization costs with degludec versus glargine U100 based on the SAEs observed in DEVOTE and in a Canadian setting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Efficient and safe glycaemic control with basal‐bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis.
- Author
-
Hochfellner, Daniel A., Rainer, Raphael, Ziko, Haris, Aberer, Felix, Simic, Amra, Lichtenegger, Katharina M., Beck, Peter, Donsa, Klaus, Pieber, Thomas R., Fruhwald, Friedrich M., Rosenkranz, Alexander R., Kamolz, Lars‐Peter, Baumann, Petra M., Mader, Julia K., and Plank, Johannes
- Subjects
INSULIN ,INSULIN derivatives ,TYPE 2 diabetes ,GLYCEMIC control ,INSULIN aspart ,DECISION support systems ,HOSPITAL patients ,BODY mass index - Abstract
Aim: To evaluate the efficacy and safety of basal‐bolus insulin therapy in managing glycaemia during fasting periods in hospitalized patients with type 2 diabetes. Materials and Methods: We performed a post hoc analysis of two prospective, uncontrolled interventional trials that applied electronic decision support system‐guided basal‐bolus (meal‐related and correction) insulin therapy. We searched for fasting periods (invasive or diagnostic procedures, medical condition) during inpatient stays. In a mixed model analysis, patientsʼ glucose levels and insulin doses on days with regular food intake were compared with days with fasting periods. Results: Out of 249 patients, 115 patients (33.9% female, age 68.3 ± 10.3 years, diabetes duration 15.1 ± 10.9 years, body mass index 30.1 ± 5.4 kg/m2, HbA1c 69 ± 20 mmol/mol) had 194 days with fasting periods. Mean daily blood glucose (BG) was lower (modelled difference [ModDiff]: −0.5 ± 0.2 mmol/L, P =.006), and the proportion of glucose values within the target range (3.9‐10.0 mmol/L) increased on days with fasting periods compared with days with regular food intake (ModDiff: +0.06 ± 0.02, P =.005). Glycaemic control on fasting days was driven by a reduction in daily bolus insulin doses (ModDiff: −11.0 ± 0.9 IU, P <.001), while basal insulin was similar (ModDiff: −1.1 ± 0.6 IU, P =.082) compared with non‐fasting days. Regarding hypoglycaemic events (BG < 3.9 mmol/L), there was no difference between fasting and non‐fasting days (χ2 0.9% vs. 1.7%, P =.174). Conclusions: When using well‐titrated basal‐bolus insulin therapy in hospitalized patients with type 2 diabetes, the basal insulin dose does not require adjustment during fasting periods to achieve safe glycaemic control, provided meal‐related bolus insulin is omitted and correction bolus insulin is tailored to glucose levels. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Hyperinsulinaemic–hypoglycaemic glucose clamps in human research: a systematic review of the literature.
- Author
-
Fabricius, Therese W., Verhulst, Clementine E. M., Kristensen, Peter L., Tack, Cees J., McCrimmon, Rory J., Heller, Simon, Evans, Mark L., Amiel, Stephanie A., Pieber, Thomas R., de Galan, Bastiaan E., and Pedersen-Bjergaard, Ulrik
- Abstract
Aims/hypothesis: The hyperinsulinaemic–hypoglycaemic glucose clamp technique has been developed and applied to assess effects of and responses to hypoglycaemia under standardised conditions. However, the degree to which the methodology of clamp studies is standardised is unclear. This systematic review examines how hyperinsulinaemic–hypoglycaemic clamps have been performed and elucidates potential important differences. Methods: A literature search in PubMed and EMBASE was conducted. Articles in English published between 1980 and 2018, involving adults with or without diabetes, were included. Results: A total of 383 articles were included. There was considerable variation in essential methodology of the hypoglycaemic clamp procedures, including the insulin dose used (49-fold difference between the lowest and the highest rate), the number of hypoglycaemic steps (range 1−6), the hypoglycaemic nadirs (range 2.0–4.3 mmol/l) and the duration (ranging from 5 to 660 min). Twenty-seven per cent of the articles reported whole blood glucose levels, most venous levels. In 70.8% of the studies, a dorsal hand vein was used for blood sampling, with some form of hand warming to arterialise venous blood in 78.8% of these. Key information was missing in 61.9% of the articles. Conclusions/interpretation: Although the hyperinsulinaemic–hypoglycaemic clamp procedure is considered the gold standard to study experimental hypoglycaemia, a uniform standard with key elements on how to perform these experiments is lacking. Methodological differences should be considered when comparing results between hypoglycaemic clamp studies. PROSPERO registration: This systematic review is registered in PROSPERO (CRD42019120083). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE.
- Author
-
Heller, Simon, Lingvay, Ildiko, Marso, Steven P., Philis‐Tsimikas, Athena, Pieber, Thomas R., Poulter, Neil R., Pratley, Richard E., Hachmann‐Nielsen, Elise, Kvist, Kajsa, Lange, Martin, Moses, Alan C., Trock Andresen, Marie, and Buse, John B.
- Subjects
TYPE 2 diabetes ,PATIENT care ,TIME perspective ,RISK perception - Abstract
Aims: The ability to differentiate patient populations with type 2 diabetes at high risk of severe hypoglycaemia could impact clinical decision making. The aim of this study was to develop a risk score, using patient characteristics, that could differentiate between populations with higher and lower 2‐year risk of severe hypoglycaemia among individuals at increased risk of cardiovascular disease. Materials and methods: Two models were developed for the risk score based on data from the DEVOTE cardiovascular outcomes trials. The first, a data‐driven machine‐learning model, used stepwise regression with bidirectional elimination to identify risk factors for severe hypoglycaemia. The second, a risk score based on known clinical risk factors accessible in clinical practice identified from the data‐driven model, included: insulin treatment regimen; diabetes duration; sex; age; and glycated haemoglobin, all at baseline. Both the data‐driven model and simple risk score were evaluated for discrimination, calibration and generalizability using data from DEVOTE, and were validated against the external LEADER cardiovascular outcomes trial dataset. Results: Both the data‐driven model and the simple risk score discriminated between patients at higher and lower hypoglycaemia risk, and performed similarly well based on the time‐dependent area under the curve index (0.63 and 0.66, respectively) over a 2‐year time horizon. Conclusions: Both the data‐driven model and the simple hypoglycaemia risk score were able to discriminate between patients at higher and lower risk of severe hypoglycaemia, the latter doing so using easily accessible clinical data. The implementation of such a tool (http://www.hyporiskscore.com/) may facilitate improved recognition of, and education about, severe hypoglycaemia risk, potentially improving patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.
- Author
-
Heller, Simon, Lingvay, Ildiko, Marso, Steven P., Philis‐Tsimikas, Athena, Pieber, Thomas R., Poulter, Neil R., Pratley, Richard E., Hachmann‐Nielsen, Elise, Kvist, Kajsa, Lange, Martin, Moses, Alan C., Andresen, Marie Trock, and Buse, John B.
- Subjects
TYPE 2 diabetes ,CARDIOVASCULAR diseases risk factors - Abstract
Aims: To undertake a post‐hoc analysis, utilizing a hypoglycaemia risk score based on DEVOTE trial data, to investigate if a high risk of severe hypoglycaemia was associated with an increased risk of cardiovascular events, and whether reduced rates of severe hypoglycaemia in patients identified as having the highest risk affected the risk of cardiovascular outcomes. Materials and Methods: The DEVOTE population was divided into quartiles according to patients' individual hypoglycaemia risk scores. For each quartile, the observed incidence and rate of severe hypoglycaemia, major adverse cardiovascular event (MACE) and all‐cause mortality were determined to investigate whether those with the highest risk of hypoglycaemia were also at the greatest risk of MACE and all‐cause mortality. In addition, treatment differences within each risk quartile [insulin degludec (degludec) vs. insulin glargine 100 units/mL (glargine U100)] in terms of severe hypoglycaemia, MACE and all‐cause mortality were investigated. Results: Patients with the highest risk scores had the highest rates of severe hypoglycaemia, MACE and all‐cause mortality. Treatment ratios between degludec and glargine U100 in the highest risk quartile were 95% confidence interval (CI) 0.56 (0.39; 0.80) (severe hypoglycaemia), 95% CI 0.76 (0.58; 0.99) (MACE) and 95% CI 0.77 (0.55; 1.07) (all‐cause mortality). Conclusions: The risk score demonstrated that a high risk of severe hypoglycaemia was associated with a high incidence of MACE and all‐cause mortality and that, in this high‐risk group, those treated with degludec had a lower incidence of MACE. These observations support the hypothesis that hypoglycaemia is a risk factor for cardiovascular events. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes.
- Author
-
Schweighofer, Natascha, Genser, Bernd, Maerz, Winfried, Kleber, Marcus E, Trummer, Olivia, Pieber, Thomas R, and Obermayer-Pietsch, Barbara
- Subjects
METFORMIN ,TYPE 2 diabetes ,ORGANIC cation transporters ,CARDIOVASCULAR diseases risk factors ,CORONARY angiography - Abstract
Purpose: Organic cation transporters (Octs) use cations like endogenous compounds, toxins, and drugs, such as metformin, as substrates. Therefore, these proteins determine the pharmacokinetics and -dynamics of metformin and thus its efficacy. Of note, metformin is today the most commonly used pharmaceutical in the treatment of type 2 diabetes (T2DM) with nevertheless a great variability in clinical response, which attributes to genetic variances. The aim of this study was to determine the influence of intronic OCT1 SNPs on prevalence of all-cause and cardiovascular death. Patients and Methods: Genotypes of 27 intronic SNPs in OCT1 were investigated in the LURIC study, a prospective cohort of 3316 participants scheduled for coronary angiography. We investigated whether these variants were associated with all-cause and cardiovascular death in 73 individuals with T2DM under metformin therapy, in individuals without diabetes, individuals with T2DM and individuals with T2DM without metformin therapy. Results: In a multivariate Cox regression analysis adjusted for classical cardiovascular risk factors, 4 intronic OCT1 SNPs were significantly associated with all-cause and cardiovascular mortality in individuals with T2DM on metformin therapy. Conclusion: According to their OCT1 genotype, some individuals with T2DM on metformin therapy might be prone to an increased risk of cardiovascular death. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
- Author
-
Evans, Marc, Moes, Robert G. J., Pedersen, Katrine S., Gundgaard, Jens, and Pieber, Thomas R.
- Subjects
MEDICAL care cost statistics ,RESEARCH ,INSULIN derivatives ,RESEARCH methodology ,HYPOGLYCEMIC agents ,EVALUATION research ,MEDICAL cooperation ,TYPE 2 diabetes ,COMPARATIVE studies ,HYPOGLYCEMIA ,DOSE-effect relationship in pharmacology ,COST effectiveness ,ETHNIC groups ,STATISTICAL models ,QUALITY-adjusted life years - Abstract
Introduction: This study aimed to evaluate the short-term cost-effectiveness of insulin degludec 200 units/mL (degludec) versus insulin glargine 300 units/mL (glargine U300) from a Dutch societal perspective.Methods: A previously published model estimated costs [2018 euros (EUR)] and effectiveness [quality-adjusted life years (QALYs)] with degludec compared with glargine U300 over a 1-year time horizon. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were informed by CONCLUDE (NCT03078478), a head-to-head randomised controlled trial in insulin-experienced patients with type 2 diabetes.Results: Treatment with degludec was associated with mean annual cost savings (EUR 24.71 per patient) relative to glargine U300, driven by a lower basal insulin dose and lower severe hypoglycaemia rate with degludec compared with glargine U300. Lower rates of non-severe nocturnal and severe hypoglycaemia resulted in improved effectiveness (+ 0.0045 QALYs) with degludec relative to glargine U300. In sensitivity analyses, changes to the vast majority of model parameters did not materially affect model outcomes.Conclusions: This short-term analysis, informed by the latest clinical trial evidence, demonstrated that degludec was a cost-effective treatment option relative to glargine U300. As such, our modelling analysis suggests that degludec would represent an efficient use of Dutch public healthcare resources in this patient population. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019.
- Author
-
Pieber, Thomas R., Bardtrum, Lars, Isendahl, Joakim, Wagner, Lily, and Nishimura, Rimei
- Subjects
- *
TYPE 2 diabetes , *INSULIN , *PEOPLE with diabetes , *HYPOGLYCEMIA , *INSULINOMA , *INSTITUTIONAL review boards - Published
- 2020
- Full Text
- View/download PDF
18. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
- Author
-
Pratley, Richard E., Husain, Mansoor, Lingvay, Ildiko, Pieber, Thomas R., Mark, Thomas, Saevereid, Hans A., Møller, Daniel Vega, and Zinman, Bernard
- Subjects
TYPE 2 diabetes ,HEART failure ,CARDIOVASCULAR diseases ,INSULIN ,PROPORTIONAL hazards models ,HYPOGLYCEMIA - Abstract
Background: Heart failure (HF) is a common cardiovascular complication of type 2 diabetes (T2D). This secondary analysis investigated baseline factors and treatment differences associated with risk of hospitalization for HF (hHF), and the possible association between severe hypoglycemia and hHF. Methods: DEVOTE was a treat-to-target, double-blind cardiovascular outcomes trial in patients (n = 7637) with T2D and high cardiovascular risk randomized to insulin degludec (degludec) or insulin glargine 100 units/mL (glargine U100). The main endpoint of this secondary analysis was time to first hHF (standardized MedDRA Query definition). Severe hypoglycemia was adjudicated (American Diabetes Association definition). The main endpoint and the temporal association between severe hypoglycemia and hHF were analyzed with a Cox proportional hazards regression model. Predictors of time to first hHF were identified using baseline variables. Results: Overall, 372 (4.9%) patients experienced hHF (550 events). There was no significant difference in the risk of hHF between treatments (hazard ratio [HR] 0.88 [0.72;1.08]
95% CI , p = 0.227). Prior HF (HR 4.89 [3.90;6.14]95% CI , p ≤ 0.0001) was the strongest predictor of future hHF events. The risk of hHF significantly increased after (HR 2.2), and within a week after (HR 11.1), experiencing a severe hypoglycemic episode compared with before an episode. Conclusions: In patients with T2D and high cardiovascular risk there were no treatment differences in terms of hHF. Prior HF was the strongest predictor of future hHF events, and there was an association between severe hypoglycemia and subsequent hHF. Further research should evaluate whether the risk of hHF can be modified by treatments aimed at reducing hypoglycemia. Trial Registration NCT01959529 [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart.
- Author
-
Pieber, Thomas R., Svehlikova, Eva, Brunner, Martina, Halberg, Inge B., Due Thomsen, Karen Margrete, and Haahr, Hanne
- Subjects
- *
TYPE 2 diabetes , *INSULIN aspart , *TYPE 1 diabetes , *FAST ions , *GLUCOSE clamp technique , *LEAST squares - Abstract
Aims: To investigate the pharmacokinetic/pharmacodynamic properties of fast‐acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in people with type 2 diabetes (T2D). Materials and methods: In a randomized, double‐blind, crossover design, 61 people with T2D usually treated with insulin ± oral antidiabetic drug(s) received single‐dose faster aspart and IAsp (0.3 U/kg) on separate visits. Blood samples for pharmacokinetic assessment were collected frequently until 12 hours post‐dose. Glucose‐lowering effect was determined in a euglycaemic clamp lasting up to 12 hours post‐dose (target 5.0 mmol/L). Results: The serum IAsp pharmacokinetic profile and glucose‐lowering effect profile were shifted to the left for faster aspart versus IAsp. Least squares mean (± SE) onset of appearance was 3.3 ± 0.3 minutes for faster aspart, which was 1.2 minutes earlier than for IAsp (95% confidence interval [CI] −1.8;−0.5; P = .001). Onset of action for faster aspart was 8.9 minutes earlier (95% CI −12.1;−5.7; P < .001) than for IAsp. During the first 30 minutes after dosing, 89% larger IAsp exposure (ratio faster aspart/IAsp 1.89 [95% CI 1.56;2.28]; P < .001) and 147% greater glucose‐lowering effect (2.47 [95% CI 1.58;6.22]; P < .001) were observed for faster aspart compared with IAsp. Offset of exposure (time to 50% of maximum IAsp concentration in the late part of the pharmacokinetic profile) occurred earlier for faster aspart (difference faster aspart – IAsp −36.4 minutes [95% CI −55.3;−17.6]; P < .001). The treatment difference of faster aspart – IAsp in offset of glucose‐lowering effect (time to 50% of maximum glucose infusion rate in the late part of the glucose infusion rate profile) was −14.4 minutes (95% CI −34.4;5.5; P = .152). Conclusions: In people with T2D, faster aspart was associated with earlier onset and greater initial exposure and glucose‐lowering effect compared with IAsp, as previously shown in people with type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
- Author
-
Pollock, Richard F., Heller, Simon, Pieber, Thomas R., Woo, Vincent, Gundgaard, Jens, Hallén, Nino, Tutkunkardas, Deniz, Luckevich, Maria, and Zinman, Bernard
- Subjects
TYPE 2 diabetes ,QUALITY-adjusted life years ,CANADIAN dollar ,CARDIOVASCULAR diseases risk factors ,MYOCARDIAL infarction ,THERAPEUTICS - Abstract
Aims: To evaluate the short‐term cost‐effectiveness of insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) from a Canadian public healthcare payer perspective in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular events and hypoglycaemia. Materials and methods: A decision analytic model was developed to estimate costs (2017 Canadian dollars [CAD]) and clinical outcomes (quality‐adjusted life years [QALYs]) with degludec vs glargine U100 over a 2‐year time horizon. The model captured first major adverse cardiovascular event, death, severe hypoglycaemia and insulin dosing. Clinical outcomes were informed by a post hoc subgroup analysis of the DEVOTE trial (NCT01959529), which compared the cardiovascular safety of degludec and glargine U100 in patients with T2D who are at high cardiovascular risk. High hypoglycaemia risk was defined as the top quartile of patients (n = 1887) based on an index of baseline hypoglycaemia risk factors. Results: In patients at high hypoglycaemia risk, degludec was associated with mean cost savings (CAD 129 per patient) relative to glargine U100, driven by a lower incidence of non‐fatal myocardial infarction, non‐fatal stroke and severe hypoglycaemia, which offset the slightly higher cost of treatment with degludec. A reduced risk of cardiovascular death and severe hypoglycaemia resulted in improved effectiveness (+0.0132 QALYs) with degludec relative to glargine U100. In sensitivity analyses, changes to the vast majority of model parameters did not materially affect model outcomes. Conclusion: Over a 2‐year period, degludec improved clinical outcomes at a lower cost as compared to glargine U100 in patients with T2D at high risk of cardiovascular events and hypoglycaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
- Author
-
Pratley, Richard E., Buse, John B., Emerson, Scott S., Franek, Edward, Gilbert, Matthew P., Marso, Steven P., McGuire, Darren K., Pieber, Thomas R., Zinman, Bernard, Hansen, Charlotte T., Hansen, Melissa V., Mark, Thomas, and Moses, Alan C.
- Subjects
TYPE 2 diabetes ,INSULIN ,AGE groups ,CARDIOVASCULAR fitness ,THERAPEUTICS - Abstract
Aims: The aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older. Materials and methods: A total of 7637 patients in the DEVOTE trial, a treat‐to‐target, randomized, double‐blind trial evaluating the CV safety of degludec vs glargine U100, were divided into three age groups (50‐64 years, n = 3682; 65‐74 years, n = 3136; ≥75 years, n = 819). Outcomes by overall age group and randomized treatment differences were analysed for major adverse cardiovascular events (MACE), all‐cause mortality, severe hypoglycaemia and serious adverse events (SAEs). Results: Patients with increasing age had higher risks of CV death, all‐cause mortality and SAEs, and there were non‐significant trends towards higher risks of MACE and severe hypoglycaemia. Treatment effects on the risk of MACE, all‐cause mortality, severe hypoglycaemia and SAEs were consistent across age groups, based on the non‐significant interactions between treatment and age with regard to these outcomes. Conclusions: There were higher risks of CV death, all‐cause mortality and SAEs, and trends towards higher risks of MACE and severe hypoglycaemia with increasing age after adjusting for baseline differences. The effects across age groups of degludec vs glargine U100 on MACE, all‐cause mortality and severe hypoglycaemia were comparable, suggesting that the risk of MACE, as well as all‐cause mortality, is similar and the risk of severe hypoglycaemia is lower with degludec regardless of age. Evidence is conclusive only until 74 years of age. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
- Author
-
Brown‐Frandsen, Kirstine, Ranthe, Mattis F., Grøn, Randi, Lange, Martin, Moses, Alan C., Örsy, Petra, Emerson, Scott S., McGuire, Darren K., Pieber, Thomas R., Poulter, Neil R., Pratley, Richard E., Zinman, Bernard, and Buse, John B.
- Subjects
GLUCAGON-like peptide-1 receptor ,CARDIOVASCULAR diseases ,MORTALITY ,INSULIN therapy ,ADVERSE health care events ,TYPE 2 diabetes - Abstract
Aim: To compare the associations between concomitant liraglutide use versus no liraglutide use and the risk of major adverse cardiovascular events (MACE) and all‐cause mortality among patients receiving basal insulin (either insulin degludec [degludec] or insulin glargine 100 units/mL [glargine U100]) in the Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE). Materials and Methods: Patients with type 2 diabetes and high cardiovascular risk were randomized 1:1 to degludec or glargine U100. Hazard ratios for MACE/mortality were calculated using a Cox regression model adjusted for treatment and time‐varying liraglutide use at any time during the trial, without interaction. Sensitivity analyses were adjusted for baseline covariates including, but not limited to, age, sex, smoking and prior cardiovascular disease. Results: At baseline, 436/7637 (5.7%) patients were treated with liraglutide; after baseline, 187/7637 (2.4%) started and 210/7637 (2.7%) stopped liraglutide. Mean liraglutide exposure from randomization was 530.2 days. Liraglutide use versus no liraglutide use was associated with significantly lower hazard rates for MACE [0.62 (0.41; 0.92)95%CI] and all‐cause mortality [0.50 (0.29; 0.88)95%CI]. There was no significant difference in the rate of severe hypoglycaemia with versus without liraglutide use. Multiple sensitivity analyses yielded similar results. Conclusions: Use of liraglutide was associated with significantly lower risk of MACE and death in patients with type 2 diabetes and high cardiovascular risk using basal insulin. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. A head‐to‐head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: Hypoglycaemia remains the weak spot.
- Author
-
Moser, Othmar, Pandis, Marlene, Aberer, Felix, Kojzar, Harald, Hochfellner, Daniel, Elsayed, Hesham, Motschnig, Melanie, Augustin, Thomas, Kreuzer, Philipp, Pieber, Thomas R., Sourij, Harald, and Mader, Julia K.
- Subjects
GLUCOSE ,DIABETES ,TYPE 2 diabetes ,HYPOGLYCEMIA ,TYPE 1 diabetes - Abstract
To compare the performance of a professional continuous glucose monitoring (proCGM) and a personal continuous glucose monitoring (persCGM) system worn in parallel under standardized conditions in individuals with type 1 diabetes (T1D), two CGM systems (iPro2 – proCGM; Minimed 640G – persCGM) worn in parallel using the same sensor (Enlite 2) were compared. Ten people with T1D were included in this single‐centre, open‐label study in which CGM performance was evaluated. The study consisted of a 24‐hours inpatient phase (meals, exercise, glycaemic challenges) and a 4‐day home phase. Analyses included fulfilment of ISO 15197:2013 criteria, mean absolute relative difference (MARD), Parkes Error Grid and Bland–Altman plots. During the inpatient stay, ISO 15197:2013 criteria fulfilment was 58.4% (proCGM) and 57.8% (persCGM). At home, the systems met ISO 15197:2013 criteria by 66.5% (proCGM) and 65.3% (persCGM). No difference of MARD in inpatient phase (19.1 ± 16.7% vs. 19.0 ± 19.6; P = 0.83) and home phase (18.6 ± 26.8% vs. 17.4 ± 21.3%, P = 0.87) was observed. All sensors performed less accurately during hypoglycaemia. ProCGM and persCGM showed similar performance during daytime and night‐time for the inpatient and the home phase. However, sensor performance was reduced during hypoglycaemia for both systems. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. GlucoTab‐guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes.
- Author
-
Aberer, Felix, Lichtenegger, Katharina M., Smajic, Edin, Donsa, Klaus, Malle, Oliver, Samonigg, Judith, Höll, Bernhard, Beck, Peter, Pieber, Thomas R., Plank, Johannes, and Mader, Julia K.
- Subjects
INSULIN therapy ,GLYCEMIC control ,HYPOGLYCEMIA ,TREATMENT of diabetes ,PEOPLE with diabetes - Abstract
Aims: To investigate efficacy, safety and usability of the GlucoTab system for glycaemic management using insulin glargine U300 in non‐critically ill hospitalized patients with type 2 diabetes (T2D). Materials and Methods: In this open, non‐controlled single‐arm pilot study, glycaemic control at the general ward of a tertiary care hospital was guided by a mobile decision support system (GlucoTab) for basal‐bolus insulin dosing using the novel basal insulin analogue insulin glargine U300 for the first time. Glycaemic control was surveilled with capillary glucose measurements and continuous glucose monitoring (CGM). The primary endpoint was efficacy of glycaemic management, defined as the percentage of blood glucose measurements within the target range of 3.9 to 7.8 mmol/L. Results: A total of 30 patients with T2D (12 female; age, 67 ± 11 years; HbA1c, 70 ± 26 mmol/mol; BMI, 31.8 ± 5.6 kg/m2; length of study, 8.5 ± 4.5 days) were included. In total, 894 capillary glucose values and 49 846 data points of CGM were available, of which 56.1% of all measured capillary glucose values and 54.3% of CGM values were within the target area (3.9‐7.8 mmol/L). Overall capillary mean glucose was 8.5 ± 1.2 and 8.4 ± 1.2 mmol/L assessed by CGM. Time within glucose target improved continuously during the course of treatment, while time within hypoglycaemia (<3.9 mmol/L) decreased substantially. The GlucoTab‐suggested total daily dose was accepted by staff in 97.3% of situations. Conclusions: Treatment with GlucoTab using insulin glargine U300 in hospitalized patients with T2D is effective and safe. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Effect of once‐weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo‐controlled, double‐blind, crossover trial.
- Author
-
Korsatko, Stefan, Jensen, Lene, Brunner, Martina, Sach‐Friedl, Stefanie, Tarp, Maja D., Holst, Anders G., Heller, Simon R., and Pieber, Thomas R.
- Subjects
TYPE 2 diabetes ,HYPOGLYCEMIA ,BLOOD sugar ,RANDOMIZED controlled trials ,PLACEBOS - Abstract
Aims: To investigate the effects of semaglutide vs placebo on glucagon and other counterregulatory hormones during hypoglycaemia in type 2 diabetes (T2D). Methods: In this double‐blind, placebo‐controlled, single‐centre trial, we randomized 38 men and women (treated only with metformin) 1:1 to 2 12‐week crossover periods of once‐weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure. The primary endpoint was change in glucagon concentration from target plasma glucose (PG) level 5.5 mmol/L to nadir (target 2.5 mmol/L). Results: The mean (range) participant age was 54.2 (41‐64) years, body mass index 29.4 (23.3‐36.1) kg/m2, glycated haemoglobin 60.8 (44.3‐83.6) mmol/mol (7.7 [6.2‐9.8]%), and diabetes duration 4.5 (0.3‐13.2) years. A total of 35 participants completed the trial and were included in the analyses. During the hypoglycaemic clamp from 5.5 mmol/L PG to nadir, the absolute change in mean glucagon concentration was similar for semaglutide vs placebo: 88.3 vs 83.1 pg/mL (estimated difference 5.2 pg/mL [95% confidence interval −7.7 to 18.1]). Concentrations of other counterregulatory hormones increased with both treatments, with a statistically significantly lower increase for noradrenaline and cortisol with semaglutide vs placebo. The glucose infusion rate to maintain constant clamp levels was similar for each treatment group, suggesting an overall similar counterregulatory response. The mean hypoglycaemic symptom score and proportion of participants recognizing hypoglycaemia during the study were lower for semaglutide vs placebo treatment at nadir, but cognitive function test results were similar. No new safety issues were observed for semaglutide. Conclusions: Semaglutide treatment did not compromise the counterregulatory glucagon response during experimental hypoglycaemia in people with T2D. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast‐acting insulin aspart compared with insulin aspart.
- Author
-
Basu, Ananda, Pieber, Thomas R., Hansen, Ann K., Sach‐friedl, Stefanie, Erichsen, Lars, Basu, Rita, and Haahr, Hanne
- Subjects
- *
GLUCOSE metabolism , *INSULIN aspart , *BLOOD sugar analysis , *GLYCEMIC control , *TYPE 2 diabetes - Abstract
Aim: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast‐acting insulin aspart (faster aspart) than with insulin aspart (IAsp). Materials and methods: In a randomized, double‐blind, crossover trial, 41 people with type 1 diabetes received identical subcutaneous single faster aspart and IAsp doses (individualized for each participant), together with a standardized mixed meal (including 75 g carbohydrate labelled with [1‐13C] glucose). PPG turnover was determined by the triple‐tracer meal method using continuous, variable [6‐3H] glucose and [6,6‐2H2] glucose infusion. Results: Insulin exposure within the first hour was 32% greater with faster aspart than with IAsp (treatment ratio faster aspart/IAsp 1.32 [95% confidence interval {CI} 1.18;1.48]; P < .001), leading to a 0.59‐mmol/L non‐significantly smaller PPG increment at 1 hour (ΔPG1h; treatment difference faster aspart–IAsp −0.59 mmol/L [95% CI –1.19; 0.01]; P = .055). The trend towards reduced ΔPG1h with faster aspart was attributable to 12% greater suppression of endogenous glucose production (EGP; treatment ratio 1.12 [95% CI 1.01; 1.25]; P = .040) and 23% higher glucose disappearance (1.23 [95% CI 1.05; 1.45]; P = .012) with faster aspart than with IAsp during the first hour. Suppression of free fatty acid levels during the first hour was 36% greater for faster aspart than for IAsp (1.36 [95% CI 1.01;1.88]; P = .042). Conclusions: The trend towards improved PPG control with faster aspart vs IAsp in this study was attributable to both greater early suppression of EGP and stimulation of glucose disappearance. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes
- Author
-
Haluzík, Martin, Fulcher, Greg, Pieber, Thomas R., Bardtrum, Lars, Tutkunkardas, Deniz, and Rodbard, Helena W.
- Subjects
PHYSIOLOGICAL effects of insulin ,GLUCOSE in the body ,BLOOD plasma ,HEMOGLOBINS ,BODY mass index - Abstract
Aims: To investigate whether the proven benefits of insulin degludec (IDeg) combined with insulin aspart (IAsp), known as IDegAsp, given twice daily, extend across a wide spectrum of patients with diabetes. Materials and methods: This was a post hoc pooled analysis of 5 phase III randomized, 26‐week, open‐label, treat‐to‐target trials comparing IDegAsp twice daily (n = 1111) with one of two comparators: premixed insulin (biphasic insulin aspart 30 [BIAsp 30]) twice daily (n = 561) or IDeg once daily + IAsp (n = 136). Patient data were stratified according to baseline glycated haemoglobin (HbA1c) or fasting plasma glucose (FPG) categories, as well as by baseline duration of diabetes or body mass index (BMI) categories. Results: We conducted a meta‐analysis of 5 clinical trials: NCT01513590, NCT01009580, NCT01059812, NCT01680341 and NCT01713530. End‐of‐trial results were broadly consistent, with differences between IDegAsp and comparators observed in phase III trials. HbA1c results were similar for IDegAsp and the comparators in all baseline characteristic (HbA1c, duration of diabetes or BMI) and category groups (number ranges). Significantly lower FPG level was observed with IDegAsp vs comparators in all baseline characteristic and most category groups (excluding FPG <5.5 mmol/L). Significantly lower insulin doses were observed with IDegAsp vs comparators in all baseline characteristic and half of the category groups, and significantly lower rates of confirmed and nocturnal confirmed hypoglycaemia were observed with IDegAsp vs comparators in all baseline variable and category groups. Conclusions: IDegAsp retains a consistent safety and efficacy profile in patients with different baseline characteristics. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
- Author
-
Davies, Melanie, Pieber, Thomas R., Hartoft-Nielsen, Marie-Louise, Hansen, Oluf K. H., Jabbour, Serge, and Rosenstock, Julio
- Subjects
- *
GLUCAGON-like peptide 1 , *GLYCEMIC control , *PLACEBOS , *TYPE 2 diabetes treatment , *TREATMENT effectiveness , *PEOPLE with diabetes , *ORAL drug administration , *CLINICAL trials , *THERAPEUTICS , *HEALTH , *BLOOD sugar analysis , *SUBCUTANEOUS injections , *BLOOD sugar , *COMPARATIVE studies , *DOSE-effect relationship in pharmacology , *GLYCOSYLATED hemoglobin , *HYPOGLYCEMIA , *HYPOGLYCEMIC agents , *RESEARCH methodology , *MEDICAL cooperation , *NAUSEA , *TYPE 2 diabetes , *RESEARCH , *STATISTICAL sampling , *EVALUATION research , *RANDOMIZED controlled trials , *GLUCAGON-like peptides - Abstract
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.Objectives: To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.Design, Setting, and Patients: Phase 2, randomized, parallel-group, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clinics, general practices, and clinical research centers) in 14 countries conducted between December 2013 and December 2014. Of 1106 participants assessed, 632 with type 2 diabetes and insufficient glycemic control using diet and exercise alone or a stable dose of metformin were randomized. Randomization was stratified by metformin use.Interventions: Once-daily oral semaglutide of 2.5 mg (n = 70), 5 mg (n = 70), 10 mg (n = 70), 20 mg (n = 70), 40-mg 4-week dose escalation (standard escalation; n = 71), 40-mg 8-week dose escalation (slow escalation; n = 70), 40-mg 2-week dose escalation (fast escalation, n = 70), oral placebo (n = 71; double-blind) or once-weekly subcutaneous semaglutide of 1.0 mg (n = 70) for 26 weeks.Main Outcomes and Measures: The primary end point was change in hemoglobin A1c (HbA1c) from baseline to week 26. Secondary end points included change from baseline in body weight and adverse events.Results: Baseline characteristics were comparable across treatment groups. Of the 632 randomized patients (mean age, 57.1 years [SD, 10.6]; men, 395 (62.7%); diabetes duration, 6.3 years [SD, 5.2]; body weight, 92.3 kg [SD, 16.8]; BMI, 31.7 [SD, 4.3]), 583 (92%) completed the trial. Mean change in HbA1c level from baseline to week 26 decreased with oral semaglutide (dosage-dependent range, -0.7% to -1.9%) and subcutaneous semaglutide (-1.9%) and placebo (-0.3%); oral semaglutide reductions were significant vs placebo (dosage-dependent estimated treatment difference [ETD] range for oral semaglutide vs placebo, -0.4% to -1.6%; P = .01 for 2.5 mg, <.001 for all other dosages). Reductions in body weight were greater with oral semaglutide (dosage-dependent range, -2.1 kg to -6.9 kg) and subcutaneous semaglutide (-6.4 kg) vs placebo (-1.2 kg), and significant for oral semaglutide dosages of 10 mg or more vs placebo (dosage-dependent ETD range, -0.9 to -5.7 kg; P < .001). Adverse events were reported by 63% to 86% (371 of 490 patients) in the oral semaglutide groups, 81% (56 of 69 patients) in the subcutaneous semaglutide group, and 68% (48 of 71 patients) in the placebo group; mild to moderate gastrointestinal events were most common.Conclusions and Relevance: Among patients with type 2 diabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks. These findings support phase 3 studies to assess longer-term and clinical outcomes, as well as safety.Trial Registration: clinicaltrials.gov Identifier: NCT01923181. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
29. LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.
- Author
-
Rutten, Guy E. H. M., Tack, Cees J., Pieber, Thomas R., Comlekci, Abdurrahman, Dynnes Ørsted, David, Baeres, Florian M. M., Marso, Steven P., and Buse, John B.
- Subjects
DIABETES ,CARBOHYDRATE intolerance ,ENDOCRINE diseases ,TYPE 2 diabetes ,CARBOHYDRATE metabolism disorders - Abstract
Aims: To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and morbidity. Methods: Baseline data, stratified for prior cardiovascular disease (CVD), were compared using multivariable logistic regression analysis to establish whether region is an independent determinant of achieved targets for glycated hemoglobin (HbA1c), blood pressure (BP), and low-density lipoprotein (LDL)-cholesterol. Results: Independent of CVD history, US participants were more often of non-White origin and had a longer history of type 2 diabetes, higher body weight, and higher baseline HbA1c. They had substantially lower systolic and diastolic BP, and a marginally lower LDL-cholesterol level. Fewer US participants were diagnosed with left ventricular dysfunction. In the largest group of patients, those with prior CVD and the highest cardiovascular risk, US participants were more often female, had a higher waist circumference, and had a decreased estimated glomerular filtration rate, but less frequently prior myocardial infarction or angina pectoris. Conclusions: There were baseline differences between US and European participants. These differences may result from variation in regional targets for cardiovascular risk factor management, and should be considered in the analysis and reporting of the trial results. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
- Author
-
Ferrannini, Ele, Baldi, Simona, Frascerra, Silvia, Astiarraga, Brenno, Heise, Tim, Bizzotto, Roberto, Mari, Andrea, Pieber, Thomas R., and Muscelli, Elza
- Subjects
GLYCOSURIA ,HOMEOSTASIS ,TYPE 2 diabetes ,SODIUM cotransport systems ,LIPIDS ,DRUG side effects - Abstract
Pharmacologically induced glycosuria elicits adaptive responses in glucose homeostasis and hormone release. In type 2 diabetes (T2D), along with decrements in plasma glucose and insulin levels and increments in glucagon release, sodium-glucose cotransporter 2 (SGLT2) inhibitors induce stimulation of endogenous glucose production (EGP) and a suppression of tissue glucose disposal (TGD). We measured fasting and postmeal glucose fluxes in 25 subjects without diabetes using a double glucose tracer technique; in these subjects and in 66 previously reported patients with T2D, we also estimated lipolysis (from [(2)H5]glycerol turnover rate and circulating free fatty acids, glycerol, and triglycerides), lipid oxidation (LOx; by indirect calorimetry), and ketogenesis (from circulating β-hydroxybutyrate concentrations). In both groups, empagliflozin administration raised EGP, lowered TGD, and stimulated lipolysis, LOx, and ketogenesis. The pattern of glycosuria-induced changes was similar in subjects without diabetes and in those with T2D but quantitatively smaller in the former. With chronic (4 weeks) versus acute (first dose) drug administration, glucose flux responses were attenuated, whereas lipid responses were enhanced; in patients with T2D, fasting β-hydroxybutyrate levels rose from 246 ± 288 to 561 ± 596 µmol/L (P < 0.01). We conclude that by shunting substantial amounts of carbohydrate into urine, SGLT2-mediated glycosuria results in a progressive shift in fuel utilization toward fatty substrates. The associated hormonal milieu (lower insulin-to-glucagon ratio) favors glucose release and ketogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes.
- Author
-
Tripolt, Norbert J., Narath, Sophie H., Eder, Michaela, Pieber, Thomas R., Wascher, Thomas C, and Sourij, Harald
- Subjects
TYPE 2 diabetes treatment ,ATHEROSCLEROSIS treatment ,DISEASE progression ,CAROTID intima-media thickness ,PROGENITOR cells ,BLOOD pressure ,BLOOD sugar - Abstract
Background Patients with rapid progression of carotid intima media thickness (CIMT) were shown to have a higher future risk for cardiovascular events. The aim of this study was to investigate the impact of multiple risk factor intervention on CIMT progression and to establish whether new cardiovascular surrogate measurements would allow prediction of CIMT changes. Materials and methods In this prospective, open, 2-years study, we included 97 patients with type 2 diabetes and at least two insufficiently treated cardiovascular risk factors, i.e. HbA
1c > 7.5% (58 mmol/mol); LDL-cholesterol >3.1mmol/l or blood pressure >140/90mmHg. Treatment was intensified according to current guidelines over 3 months with the aim to maintain intensification over 2 years. The primary outcome was the change in CIMT after 2 years. We also assessed markers of mechanical and biochemical endothelial function and endothelial progenitor cells before and after 3 months of treatment intensification. For testing differences between before and after multifactorial treatment measurements we used either the paired student's t-test or the Wilcoxon signed-rank test, depending on the distribution of the data. Additional, explorative statistical data analysis was done on CIMT progression building a linear multivariate regression model. Results Blood glucose, lipids and blood pressure significantly improved during the first 3 months of intensified treatment, which was sustained over the 2-year study duration. Mean CIMT significantly decreased from baseline to 2 year (0.883 ± 0.120mm vs. 0.860 ± 0.130mm; p = 0.021). None of the investigated surrogate measures, however, was able to predict changes in IMT early after treatment intensification. Conclusions Intensification of risk factor intervention in type 2 diabetes results in CIMT regression over a period of 2 years. None of the biomarkers used including endothelial function parameters or endothelial progenitor cells turned out to be useful to predict CIMT changes. Trial registration Clinical Trial Registration - URL: http://clinicaltrials.gov/show/NCT00660790 Unique identifier: NCT00660790 [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
32. Lipid-Heparin Infusion Suppresses the IL-10 Response to Trauma in Subcutaneous Adipose Tissue in Humans.
- Author
-
Ikeoka, Dimas T., Pachler, Christoph, Mader, Julia K., Bock, Gerlies, Neves, Ana L., Svehlikova, Eva, Feichtner, Franz, Koehler, Gerd, Wrighton, Christopher J., Pieber, Thomas R., and Ellmerer, Martin
- Subjects
HEPARIN ,LIPIDS ,INTERLEUKIN-10 ,ADIPOSE tissues ,CYTOKINES ,OBESITY ,TYPE 2 diabetes - Abstract
An imbalance between pro- and anti-inflammatory cytokine productions in adipose tissue is thought to contribute to chronic, systemic, low-grade inflammation and consequently to an increased risk of cardiovascular complications in obese and type 2 diabetic patients. Nonesterified fatty acids (NEFA), whose serum levels are elevated in such patients, have been shown to interfere with cytokine production in vitro. In order to evaluate the effects of elevated NEFA levels on cytokine production in adipose tissue in vivo we used an 18-gauge open-flow microperfusion (OFM) catheter to induce local inflammation in the subcutaneous adipose tissue (SAT) of healthy volunteers and to sample interstitial fluid (IF) specifically from the inflamed tissue. In two crossover studies, nine subjects received either an intravenous lipid-heparin infusion to elevate circulating NEFA levels or saline over a period of 28 h. The former increased the circulating levels of triglycerides (TGs), NEFA, glucose, and insulin over the study period. NEFA effects on locally induced inflammation were estimated by measuring the levels of a panel adipokines in the OFM probe effluent. Interleukin-6 (IL-6), IL-8, tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) levels increased during the study period but were not affected by lipid-heparin infusion. In contrast, the level of IL-10, an anti-inflammatory cytokine, was significantly reduced during the final hour of lipid-heparin infusion (saline: 449.2 ± 105.9 vs. lipid-heparin: 65.4 ± 15.4 pg/ml; P = 0.02). These data provide the first in vivo evidence that elevated NEFA can modulate cytokine production by adipose tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
33. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome.
- Author
-
Wehr, Elisabeth, Schweighofer, Natascha, Möller, Reinhard, Giuliani, Albrecht, Pieber, Thomas R., and Obermayer-Pietsch, Barbara
- Subjects
POLYCYSTIC ovary syndrome ,OBESITY ,GLUCOSE tolerance tests ,TYPE 2 diabetes ,ENDOCRINE diseases ,BODY mass index ,TESTOSTERONE ,HYPERANDROGENISM ,DISEASES in women - Abstract
Abstract: Variants in the fat mass and obesity–associated gene (FTO) are associated with obesity and type 2 diabetes mellitus. Women with polycystic ovary syndrome (PCOS) are frequently affected by obesity and impaired glucose tolerance. The aim of this study was to investigate the impact of FTO variants (rs9939609) on metabolic and endocrine parameters in PCOS women. We genotyped the single nucleotide polymorphism rs9939609 (T/A) in 288 PCOS women and performed metabolic and hormonal measurements, oral glucose tolerance test, hirsutism score, and lipometry. The A/T + A/A genotype showed an increased prevalence in overweight/obese PCOS patients (odds ratio [OR] = 1.91, P = .028) and in PCOS women with impaired glucose tolerance (OR = 3.23, P = .009). The A allele was associated with a significant increase in free testosterone (P = .042), weight (P = .024), body mass index (P = .011), 2-hour glucose (P = .047), 1-hour insulin (P = .032), and AUCins (area under the curve insulin) (P = .038). In a logistic regression analysis, the A allele was associated with free testosterone (P = .025; OR = 1.54; 95% confidence interval, 1.06-2.25; B = 0.86). Total body fat (percentage) (P = .016), total fat mass (P = .013), visceral adipose tissue mass (P = .044), and subcutaneous fat mass (P = .011) were significantly increased in PCOS women carrying the A allele. We demonstrated that variants within the FTO gene influence hyperandrogenemia and anthropometric parameters in women with PCOS, indicating an important role of FTO variants not only in obesity and diabetes but also in hyperandrogenism in women with PCOS. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
34. Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus.
- Author
-
Plank, Johannes, Siebenhofer, Andrea, Berghold, Andrea, Jeitler, Klaus, Horvath, Karl, Mrak, Peter, and Pieber, Thomas R.
- Subjects
INSULIN therapy effectiveness ,INSULIN therapy testing ,META-analysis ,DIABETES ,TYPE 2 diabetes ,INSULIN derivatives ,PEOPLE with diabetes - Abstract
Background This article compares the effect of treatment with short-acting insulin (SAI) analogues vs regular insulin on glycemic control, hypoglycemic episodes, quality of life, and diabetes-specific complications. Methods Electronic searches (Cochrane Library, MEDLINE, and EMBASE) and additional searching (pharmaceutical companies, experts, approval agencies, abstracts of diabetology meetings) were performed. Two reviewers independently screened randomized controlled trials to determine inclusion. Results Forty-two randomized controlled trials that assessed the effect of SAI analogues vs regular insulin in 7933 patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes mellitus were identified. The weighted mean difference between hemoglobin A
1c values obtained using SAI analogues and regular insulin was -0.12% (95% confidence interval [CI], -0.17% to -0.07%) for adult patients with type 1 diabetes mellitus and -0.02% (95% CI, -0.10% to 0.07%) for patients with type 2 diabetes mellitus. The standardized mean difference for overall hypoglycemia (episodes per patient per month) was -0.05 (95% CI, -0.22 to 0.11) and -0.04 (95% CI, -0.12 to 0.04) comparing SAI analogues with regular insulin in adult patients with type 1 and type 2 diabetes mellitus, respectively. No differences between treatments were observed in children with type 1 diabetes, pregnant women with type 1 diabetes mellitus, and women with gestational diabetes. Concerning quality of life, improvement was observed only in open-label studies in patients with type 1 diabetes mellitus. No differences were seen in a double-blinded study of patients with type 1 or in the studies of patients with type 2 diabetes mellitus. Conclusion Our analysis suggests only a minor benefit to hemoglobin A1c values in adult patients with type 1 diabetes mellitus but no benefit in the remaining population with type 2 or gestational diabetes from SAI analogue treatment. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
35. EndoBarrier™ Implantation Rapidly Improves Insulin Sensitivity in Obese Individuals with Type 2 Diabetes Mellitus.
- Author
-
Obermayer, Anna, Tripolt, Norbert J., Aziz, Faisal, Högenauer, Christoph, Aberer, Felix, Schreiber, Florian, Eherer, Andreas, Sourij, Caren, Stadlbauer, Vanessa, Svehlikova, Eva, Brunner, Martina, Goswami, Nandu, Kojzar, Harald, Pferschy, Peter N., Pieber, Thomas R., and Sourij, Harald
- Subjects
TYPE 2 diabetes ,INSULIN sensitivity ,GLYCOSYLATED hemoglobin ,WEIGHT loss ,ADIPOSE tissues ,GASTRIC bypass ,UMBILICAL cord clamping - Abstract
The EndoBarrier™ medical device is a duodenal-jejunal bypass liner designed to mimic the effects of gastric bypass surgery to induce weight loss and glycaemic improvement. In this study, 10 participants with type 2 diabetes mellitus (T2DM), a mean body mass index (BMI) of 43.3 ± 5.0 (kg/m
2 ) and a mean glycated haemoglobin A1c (HbA1c) of 60.6 ± 8.6 mmol/mol were examined at baseline (before implantation of EndoBarrier™), 4 weeks after implantation, at 36 weeks (right before explantation) and 24 weeks after the removal of the device to explore the short and long-term effects on glucose metabolism. Besides a significant reduction in body weight and fat mass, EndoBarrier™ treatment significantly improved insulin sensitivity during Botnia clamp investigations after four weeks of implantation. The beneficial effects decreased over time but remained significant 24 weeks after removal of the device. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
36. Evaluation of a Teaching and Treatment Program in Over 4,000 Type 2 Diabetic Patients After Introduction of Reimbursement Policy for Physicians.
- Author
-
Korsatko, Stefan, Habacher, Wolfgang, Rakovac, Ivo, Plank, Johannes, Seereiner, Sabine, Beck, Peter, Gfrerer, Robert, Mrak, Peter, Bauer, Bernd, Großschädl, Manfred, and Pieber, Thomas R.
- Subjects
PATIENT education ,TYPE 2 diabetes ,DISEASE management ,DIABETES complications ,BODY weight ,CHOLESTEROL - Abstract
The article discusses a study which evaluated the overall acceptance and effectiveness of the Styrian Diabetes Type 2 Education Project in Austria four years after its systemic implementation. The program covers areas such as basic diabetes information, self-monitoring, medication and hypoglycemia and late complications. The study noted the improvement in all target parameters such as body weight and cholesterol during the project years. Other significant findings of the study are cited.
- Published
- 2007
- Full Text
- View/download PDF
37. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
- Author
-
Marso, Steven P., McGuire, Darren K., Zinman, Bernard, Poulter, Neil R., Emerson, Scott S., Pieber, Thomas R., Pratley, Richard E., Haahr, Poul-Martin, Lange, Martin, Brown-Frandsen, Kirstine, Moses, Alan, Skibsted, Simon, Kvist, Kajsa, Buse, John B., and DEVOTE Study Group
- Subjects
- *
INSULIN , *DIABETES in children , *DIABETES in adolescence , *MYOCARDIAL infarction , *CORONARY heart disease prevention , *DRUG efficacy , *THERAPEUTICS , *BLOOD sugar analysis , *TYPE 2 diabetes complications , *CARDIOVASCULAR diseases , *COMPARATIVE studies , *HYPOGLYCEMIA , *HYPOGLYCEMIC agents , *INSULIN derivatives , *RESEARCH methodology , *MEDICAL cooperation , *TYPE 2 diabetes , *RESEARCH , *RESEARCH funding , *STATISTICAL sampling , *EVALUATION research , *RANDOMIZED controlled trials , *DISEASE incidence , *BLIND experiment , *KAPLAN-Meier estimator - Abstract
Background: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec.Methods: We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial. The primary composite outcome in the time-to-event analysis was the first occurrence of an adjudicated major cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) with a prespecified noninferiority margin of 1.3. Adjudicated severe hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity-adjusted secondary outcome.Results: Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin level was 8.4±1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean glycated hemoglobin level was 7.5±1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec group than in the glargine group (128±56 vs. 136±57 mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority). Rates of adverse events did not differ between the two groups.Conclusions: Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events. (Funded by Novo Nordisk and others; DEVOTE ClinicalTrials.gov number, NCT01959529 .). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
38. Impact of errors in paper-based and computerized diabetes management with decision support for hospitalized patients with type 2 diabetes. A post-hoc analysis of a before and after study.
- Author
-
Donsa, Klaus, Beck, Peter, Höll, Bernhard, Mader, Julia K., Schaupp, Lukas, Plank, Johannes, Neubauer, Katharina M., Baumgartner, Christian, and Pieber, Thomas R.
- Subjects
- *
PEOPLE with diabetes , *BLOOD sugar , *DRUG side effects , *MEDICAL decision making , *DISEASE management , *COMPUTERS in medicine , *ALGORITHMS , *COMPARATIVE studies , *DECISION support systems , *DOCUMENTATION , *INDUSTRIES , *INFORMATION storage & retrieval systems , *MEDICAL databases , *INSULIN , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL errors , *TYPE 2 diabetes , *RESEARCH , *EVALUATION research - Abstract
Objective: Most preventable adverse drug events and medication errors occur during medication ordering. Medication order entry and clinical decision support are available on paper or as computerized systems. In this post-hoc analysis we investigated frequency and clinical impact of blood glucose (BG) documentation- and user-related calculation errors as well as workflow deviations in diabetes management. We aimed to compare a paper-based protocol to a computerized medication management system combined with clinical workflow and decision support.Methods: Seventy-nine hospitalized patients with type 2 diabetes mellitus were treated with an algorithm driven basal-bolus insulin regimen. BG measurements, which were the basis for insulin dose calculations, were manually entered either into the paper-based workflow protocol (PaperG: 37 patients) or into GlucoTab(®)-a mobile tablet PC based system (CompG: 42 patients). We used BG values from the laboratory information system as a reference. A workflow simulator was used to determine user calculation errors as well as workflow deviations and to estimate the effect of errors on insulin doses. The clinical impact of insulin dosing errors and workflow deviations on hypo- and hyperglycemia was investigated.Results: The BG documentation error rate was similar for PaperG (4.9%) and CompG group (4.0%). In PaperG group, 11.1% of manual insulin dose calculations were erroneous and the odds ratio (OR) of a hypoglycemic event following an insulin dosing error was 3.1 (95% CI: 1.4-6.8). The number of BG values influenced by insulin dosing errors was eightfold higher than in the CompG group. In the CompG group, workflow deviations occurred in 5.0% of the tasks which led to an increased likelihood of hyperglycemia, OR 2.2 (95% CI: 1.1-4.6).Discussion: Manual insulin dose calculations were the major source of error and had a particularly strong influence on hypoglycemia. By using GlucoTab(®), user calculation errors were entirely excluded. The immediate availability and automated handling of BG values from medical devices directly at the point of care has a high potential to reduce errors. Computerized systems facilitate the safe use of more complex insulin dosing algorithms without compromising usability. In CompG group, missed or delayed tasks had a significant effect on hyperglycemia, while in PaperG group insufficient precision of documentation times limited analysis. The use of old BG measurements was clinically less relevant.Conclusion: Insulin dosing errors and workflow deviations led to measurable changes in clinical outcome. Diabetes management systems including decision support should address nurses as well as physicians in a computerized way. Our analysis shows that such systems reduce the frequency of errors and therefore decrease the probability of hypo- and hyperglycemia. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
39. Taking a Closer Look-Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients with Type 2 Diabetes Mellitus Under Basal-Bolus Insulin Therapy.
- Author
-
Schaupp, Lukas, Donsa, Klaus, Neubauer, Katharina M., Mader, Julia K., Aberer, Felix, Höll, Bernhard, Spat, Stephan, Augustin, Thomas, Beck, Peter, Pieber, Thomas R., and Plank, Johannes
- Subjects
- *
BLOOD sugar , *BLOOD sugar monitors , *TYPE 2 diabetes , *GLUCAGON , *INSULIN therapy - Abstract
Background: Inpatient glucose management is based on four daily capillary blood glucose (BG) measurements. The aim was to test the capability of continuous glucose monitoring (CGM) for assessing the clinical impact and safety of basal-bolus insulin therapy in non-critically ill hospitalized patients with type 2 diabetes mellitus (T2DM). Materials and Methods: Eighty-four patients with T2DM (age, 68±10 years; glycosylated hemoglobin, 72±28 mmol/mol; body mass index, 31±7 kg/m2) were treated with basal-bolus insulin. CGM was performed with the iPro®2 system (Medtronic MiniMed, Northridge, CA) and calibrated retrospectively. Results: A remarkable consistency between CGM and BG measurements and therapy improvement was shown over the study period of 501 patient-days. The number of CGM and BG measurements (CGM/BG) in the range from 3.9-10 mmol/L increased from 67.7%/67.2% (on Day 1) to 77.5%/78.6% (on the last day) ( P<0.04). The number of low glycemic episodes (3.3 to <3.9 mmol/L) during nighttime detected by CGM was 15-fold higher, and the number of episodes >13.9 mmol/L detected by CGM during night was 12.5-fold higher than the values from the BG measurements. Ninety-nine percent of data points were in the clinically accurate or acceptable Clarke Error Grid Zones A+B, and the relative numbers of correctly identified episodes of <3.9 and >13.9 mmol/L detected by CGM (sensitivity) were 47.3% and 81.5%, respectively. Conclusions: Our data exhibit a good agreement between overall CGM and BG measurements, but there were a high number of missed hypo- and hyperglycemic episodes with BG measurements, particularly during nighttime. Overall assessment of glycemic control using CGM is feasible, whereas the use of CGM for individualized therapy decisions needs further improvement. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
40. Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.
- Author
-
Lam, Uyen D.P., Lerchbaum, Elisabeth, Schweighofer, Natascha, Trummer, Olivia, Eberhard, Katharina, Genser, Bernd, Pieber, Thomas R., and Obermayer-Pietsch, Barbara
- Subjects
- *
INSULIN , *POLYCYSTIC ovary syndrome , *OBESITY , *TYPE 2 diabetes , *INFLAMMATION , *BIOLOGICAL variation - Abstract
Abstract: Polycystic ovary syndrome (PCOS) shows not only hyperandrogenemia, hirsutism and fertility problems, but also metabolic disturbances including obesity, cardiovascular events and type-2 diabetes. Accumulating evidence suggests some degree of inflammation associated with prominent aspects of PCOS. We aimed to investigate the association of genetic variants 3′UTR rs17468190 (G/T) of the inflammation-associated gene MEP1A (GenBank ID: NM_005588.2) with metabolic disturbances in PCOS and healthy control women. Genetic variants rs17468190 (G/T) of MEP1A gene were analyzed in 576 PCOS women and 206 controls by using the Taqman fluorogenic 5′-exonuclease assay. This polymorphism was tested for association with anthropometric, metabolic, hormonal, and functional parameters of PCOS. There was a borderline significant difference in genotype distribution between PCOS and control women (p=0.046). In overweight/obese PCOS patients, the variants rs17468190 (G/T) in the MEP1A gene are associated with glucose and insulin metabolism. In a dominant model, the GG genotype of the MEP1A gene was more strongly associated with insulin metabolism in overweight/obese PCOS women (body mass index, BMI>25kg/m2), than in GT+TT genotypes. The MEP1A GG-carriers showed a significantly increased homeostatic model assessment — insulin resistance (HOMA-IR) (p=0.003), elevation of fasting insulin (p=0.004) and stimulated insulin (30min, p<0.001; 60min, p=0.009; 120min, p=0.009) as well as triglyceride (p=0.032) levels. MEP1A is a possible target gene for disease modification in PCOS. It might contribute to the abnormalities of glucose metabolism and insulin sensitivity and serve as a diagnostic or therapeutic target gene for PCOS. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
41. LC/MSIMS Method for Quantitative Determination of Long-Chain Fatty Acyl-CoAs.
- Author
-
Magnes, Christoph, Sinner, Frank M., Regittnig, Werner, and Pieber, Thomas R.
- Subjects
- *
FATTY acids , *CARBOXYLIC acids , *LIPID metabolism , *TYPE 2 diabetes , *METABOLITES , *LABORATORY rats - Abstract
Long-chain acyl-CoA esters (LCACoAs) are activated lipid species that represent key substrates in lipid metabolism. The relationship between lipid metabolism disorders and type 2 diabetes has attracted much attention to this class of metabolites. This paper presents a highly sensitive and robust on-line LC/MS² procedure for quantitative determination of LCACoAs from rat liver. A fast SPE method has been developed without the need for lime-consuming evaporation steps for sample preparation. LCACoAs were separated with high resolution using a C18 reversed-phase column at high pH (10.5) with an ammonium hydroxide and acetonitrile gradient. Five LCACoAs (C16: 0, C16:1, C18:0 C18:1, C18:2) were quantified by selective multireaction monitoring using a triple quadrupole mass spectrometer in positive electrospray ionization mode. It is possible to perform a neutral loss scan of 507 for lipid profiling of complex LCACoA mixtures in tissue extracts. The method presented was validated according to ICH guidelines for quantitative determination of five LCACoAs for physiological concentrations in 100-200 mg of tissue with accuracies ranging from 94.8 to 110.8%, interrun precisions between 2.6 and 12.2%, and intrarun precisions between 1.2 and 4.4%. Due to the high sensitivity of the developed method, the amount of tissue biopsied for reliable quantification can be reduced. This may be advantageous in the quantification of LCACoAs in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.